ClinicalTrials.gg
CompletedNCT06607354Updated Sep 24, 2024

Consuming Grass Finished Lamb Improves Blood Plasma ω-3 Fatty Acid Response Among Healthy Consumers.

An interventional study of Grass fed lamb in Healthy, sponsored by Queen's University, Belfast. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-24.

Sponsored by Queen's University, Belfast · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Registered 5 years 2 months after the study started (first participant enrolled Jun 2019, registered Sep 2024).
Phase
Not applicable
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Study summary

This study will investigate the impact of consuming grass-finished lamb meat on blood omega-3 PUFAs and cardiovascular risk factors compared to concentrate-finished lamb meat. Healthy volunteers will consume three portions of lamb meat/week from a grass-finished meat treatment or a concentrate-finished meat treatment for four weeks. Blood samples will be taken at weeks zero and four. The primary outcome is to assess difference in change in omega-3 PUFA concentration in plasma and platelets between treatment groups. The secondary outcome is to assess between groups differences in change in cardiovascular disease risk factors including blood pressure, BMI and lipids among healthy individuals.

02

Conditions studied

  • Healthy

Keywords

  • Lamb
  • Omega-3
  • Fatty acids
  • Plasma
  • Plasma phospholipids
03

In context

Lead sponsor

Queen's University, Belfast is the lead sponsor of 116 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female volunteers aged between 18-64 years old.

Exclusion criteria

Exclusion Criteria:

  • Participants with a BMI of \<18.5 km/m² and greater than >35 km/m².
  • Participants who take prescribed medication, including statins to reduce LDL cholesterol, and any form of dietary supplements (excluding vitamin D).
  • People who smoke.
  • Participants who consume more than two portions of fish per month.
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
34 participants (actual)

Study arms

  • No intervention
    Concentrate/ Cereal fed lamb

    Participants to consume three portions of lamb per week for four consecutive weeks. The lamb diet was a concentrate/cereal pellet.

  • Experimental
    Grass fed lamb

    Participants to consume three portions of lamb per week for four consecutive weeks. The lamb diet was grass only.

    Other: Grass fed lamb

Interventions

  • OtherGrass fed lamb

    This study investigated the impact of consuming grass finished lamb on total blood plasma and blood plasma phospholipids (PL) FA and on cardiovascular risk factors, including heart rate, blood pressure (BP), HDL-cholesterol, LDL-cholesterol, and TAG cholesterol, in humans.

06

What researchers measure

Primary outcomes

  1. Fatty acid (%) change in blood plasma between treatments

    Primary outcome is to assess the impact of consuming grass vs concentrate finished lamb on blood plasma response in healthy volunteers

    Time frame: Week 0 and week 4

  2. Fatty acid change (%) in blood plasma phospholipids between treatments

    Primary outcome is to assess the impact of consuming grass vs concentrate finished lamb on blood plasma phospholipid response in healthy volunteers

    Time frame: Week 0 and week 4

Secondary outcomes

  1. Change in weight (kg) in participants between treatments

    Secondary outcome is to assess the impact of consuming grass vs concentrate finished lamb on weight among healthy volunteers

    Time frame: Week 0 and week 4

  2. Change in Body Mass Index (BMI) in participants between treatments - calculated by dividing weight (kg) by height in meters squared

    Secondary outcome is to assess the impact of consuming grass vs concentrate finished lamb on weight and BMI response in healthy volunteers

    Time frame: Week 0 and week 4

  3. Cholesterol

    Secondary outcome is to assess the impact of consuming grass vs concentrate finished lamb on total cholesterol, LDL, HDL and TAG response in healthy volunteers

    Time frame: Week 0 and week 4

  4. Blood pressure (diastolic and systolic)

    Secondary outcome is to assess the impact of consuming grass vs concentrate finished lamb on blood pressure (diastolic and systolic) response in healthy volunteers

    Time frame: Week 0 and week 4

07

Study locations

1 site
  • School of Biological Sciences, Queen's University Belfast
    Belfast, BT9 5DL, United Kingdom
08

References and documents

Publications

  • Perkins LS, Nugent AP, Woodside JV, Cardwell CR, Scollan ND. Consuming grass finished lamb improves blood plasma omega-3 fatty acid response among healthy consumers. Eur J Nutr. 2025 Jul 21;64(5):242. doi: 10.1007/s00394-025-03765-z. PubMed 40690019 ↗

Study documents

  • Protocol and statistical analysis plan · Mar 22, 2019
  • Informed consent form · Mar 22, 2019

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06607354
Collaborators
Agri-Food and Biosciences Institute
Responsible party
Lynda Perkins (Postdoctoral Researcher, Queen's University, Belfast) — Principal investigator
First posted
Sep 23, 2024
Start date
Jun 20, 2019
Primary completion
Dec 13, 2019
Completion
Dec 13, 2019
Last update
Sep 24, 2024

Study contacts

Nigel D Scollan, PhD
principal investigator · Queen's University, Belfast
Jayne V Woodside, PhD
principal investigator · Queen's University, Belfast

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion